AvroBio Inc (NASDAQ: AVRO) closed the day trading at $1.22 down -4.69% from the previous closing price of $1.28. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 812323 shares were traded.
Ratios:
For a better understanding of AVRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Morgan Stanley Downgraded its Overweight to Equal-Weight on November 19, 2021, whereas the target price for the stock was revised from $24 to $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVRO now has a Market Capitalization of 56.52M and an Enterprise Value of -40.62M. As of this moment, AvroBio’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.42.
Stock Price History:
Over the past 52 weeks, AVRO has reached a high of $1.70, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is 1.3020, while the 200-Day Moving Average is calculated to be 1.3809.
Shares Statistics:
Over the past 3-months, AVRO traded about 301.97K shares per day on average, while over the past 10 days, AVRO traded about 244.14k shares per day. A total of 44.65M shares are outstanding, with a floating share count of 38.41M. Insiders hold about 14.39% of the company’s shares, while institutions hold 42.70% stake in the company. Shares short for AVRO as of Feb 29, 2024 were 121.23k with a Short Ratio of 0.40, compared to 181.46k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.27% and a Short% of Float of 0.31%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.36 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.36, while EPS last year was -$0.57. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.08 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.48 and -$1 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.44, with 3 analysts recommending between -$0.17 and -$0.65.
